EDAP TMS S.A. Reports Success, Rapidly Growing Interest at EAU Congress

10-Year Experience Data and Salvage Therapy Studies Generate Increased Interest



LYON, France, April 11  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), the global leader in high intensity focused ultrasound treatment of localized prostate cancer, experienced a significant upwelling of interest in Ablatherm(R)-HIFU at the recently concluded European Association of Urology Conference in Paris. The interest, generated from the 10 years of European experience in Ablatherm-HIFU, its recently announced success as a leading salvage therapy option for radiation failures and the company's fast growing presence throughout Europe kept EDAP's booth continuously busy with large groups of urologists inquiring about offering Ablatherm-HIFU in urology clinics around the world.

The Scientific Program of the Congress included seven scientific posters on HIFU technology presented by several scientists. All of the selected and approved abstracts on HIFU related exclusively to the use of Ablatherm-HIFU, the clear global leader. This strong interest for HIFU, and Ablatherm applied to localized prostate cancer in particular, clearly demonstrate EDAP's leadership and excellence in this field.

Several of the scientific posters related to the 10 years of Ablatherm- HIFU experience in Europe. Dr. Thuroff, from Harlaching Hospital in Munich, presented the first long-term tolerance and safety study on the use of Ablatherm-HIFU for localized prostate cancer. The data, compiled over a 10- year period and measuring 50 potential adverse events, confirm the side effect profile of patients treated as first intention therapy compared very favorably with established treatment modalities. During the congress, success rates obtained over the past 10 years were confirmed by different European user sites such as Dr. Gelet, Lyon, France, Dr. Chaussy, Munich, Germany, and Dr. Callea, Bari, Italy, with negative biopsy rates ranging from 96% to 75% for low to intermediate risk cases. The use of Ablatherm-HIFU over the last decade demonstrated a good balance between high local efficacy and low therapy induced side effects, making the Ablatherm a clear option for patients who are not candidates for surgery or who wish to avoid related side effects.

Additionally, posters presented by two different user centers addressed the use of Ablatherm-HIFU for patients showing a recurrence of cancer after radiotherapy treatment. Radiotherapy failures range from 30% to 50% of treatments. Dr. F. Murat, Lyon, France, presented a cohort of patients who failed radiotherapy and opted for an Ablatherm procedure as a salvage option, with success rates ranging from 76.5% up to 84%, with limited side effects compared to current treatment modalities. Dr. Bensadoum, Caen, France, highlighted post-operative low side effects rates associated with the use of Ablatherm-HIFU on patients who failed radiotherapy. These two presentations concluded that with its unique side effects to efficacy ratio, Ablatherm-HIFU was to become the gold standard for external beam radiation failures.

Rafael Varona, Medical Director of EDAP commented, "Clearly there is a fast growing consensus among urologists that Ablatherm-HIFU therapy in particular offers significant advantages to a growing number of patients bringing interest to previously unheard of levels. Although there is a wide choice of treatment for localized prostate cancer, Ablatherm-HIFU is a clearly compelling choice for patients who are not candidates for surgery or who failed a radiotherapy treatment. It is also an attractive option for men seeking a less invasive therapy preserving their quality of life. Our clinical results are not only the most extensive by a significant margin, but also clearly show our outcomes, in terms of efficacy, to be at levels rivaling all standard therapies."

During the conference EDAP also hosted a Symposium on Ablatherm-HIFU gathering more than 350 urologists, all existing and potential Ablatherm HIFU users. This Symposium included presentations by significant luminaries within the European urology community who are also experienced practitioners using Ablatherm-HIFU. Following the Symposium all participants together with all EDAP's worldwide agents and distributors celebrated the 10 years of experience with Ablatherm-HIFU. Strong proximity with early adopters of Ablatherm-HIFU is a key to the long-term success of Ablatherm-HIFU applied to localized prostate cancer.

The European HIFU Club met on Friday, April 7, with strong attendance reflecting the fast growing interest for Ablatherm-HIFU. Lecture and discussion forums were held on advances in the best-in-class Ablatherm-HIFU integrated imaging system, preservation of continence and potency, treatment of large-volume prostates, the comprehensive Ablatherm-HIFU learning curve, HIFU history and patient discussions and concerns in learning about Ablatherm- HIFU. The advanced integrated imaging system launched by EDAP in April of 2005 is allowing users to more completely visualize the prostate and directly apply energy to the diseased prostate while offering the opportunity to see continuing reduction in side effects.

During the entirety of the conference, the EDAP booth was lined with urologists seeking more information on this treatment option, especially due to EDAP's highly flexible per procedure model and supportive training program, which uniquely allows urologists to quickly gain access to Ablatherm-HIFU treatments while getting top results from the time they begin offering the therapy. EDAP's rapidly growing per-procedure business model reflects a clear understanding of the European clinical setting and the Company's deep commitment to assist physicians in offering this therapy to their patients.

"Our reception at the EAU Congress was by far the largest interest we have ever seen in this therapy and clearly indicative of our entry to the ranks of mainstream choices for localized prostate cancer," said Hugues de Bantel, CEO of EDAP. "EDAP with the Ablatherm-HIFU is, without any doubt, considered the global leader in HIFU therapy for localized prostate cancer based on the strongest long-term clinical outcomes available with the lowest side effects. Only the Ablatherm-HIFU can demonstrate clear and thoroughly credible data from multiple centers proving long-term efficacy of this treatment combined with low side effects. The results on radiotherapy failures clearly position Ablatherm-HIFU as the potential gold standard for radiation failure patients. Our growing acceptance by the medical and scientific communities across Europe and locations worldwide is a clear acknowledgement of our focus on verifiable clinical success, technological advancement and constant emphasis on Ablatherm-HIFU training to give doctors the best course of HIFU care available today."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Halliburton Investor Relations at [phone], the Corporate Investor Relations Dept at [phone] or see the Company's Web site at: http://www.edap-tms.com/.

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is not yet FDA approved or marketed in the United States.

  CONTACT:     EDAP TMS S.A.
               Hugues de Bantel - Philippe Chauveau
               Blandine Confort
               [phone]

               Halliburton Investor Relations
               Matt Kreps - Geralyn DeBusk
               972 458 8000


DATASOURCE: EDAP TMS S.A.



Contact: Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all of

EDAP TMS S.A., all at [phone]; or Matt Kreps, or Geralyn DeBusk,

both of Halliburton Investor Relations, both at [phone]



Web site:  http://www.edap-tms.com/

Copyright